提示: 手机请竖屏浏览!

国际癌症研究机构有关结直肠癌筛查的观点
The IARC Perspective on Colorectal Cancer Screening


Béatrice Lauby-Secretan ... 肿瘤 • 2018.05.03
相关阅读
• 根据基线腺瘤检查结果判断远期结直肠癌风险 • 个性化的结直肠癌筛查 • 使用粪便免疫化学测试进行6轮结直肠癌筛查 • 更新版结直肠癌筛查建议

结直肠癌是男性中第三、女性中第二最常见癌症,代表全球每年癌症发病率中的近10%1。结直肠癌的发病率随经济发展水平的提高呈明显正梯度分布2。虽然如此,五年净生存率却随收入水平的下降而下降,高收入国家的这一生存率达到60%,而低收入国家则只有30%或更低3

已确定的结直肠癌危险因素包括食用加工肉类4、饮用酒精饮料5、吸烟5、体脂过多6,而膳食纤维和乳制品的摄入及体育活动水平的增加会降低结直肠癌风险7,8。此外,某些亚群由于遗传易感性(例如Lynch综合征)、结直肠瘤变的家族史或个人史或者与结直肠癌相关的疾病(例如炎性肠病),患结直肠癌的风险增加。





作者信息

Béatrice Lauby-Secretan, Ph.D., Nadia Vilahur, Ph.D., Franca Bianchini, Ph.D., Neela Guha, Ph.D., M.P.H., and Kurt Straif, M.P.H., M.D., Ph.D. for the International Agency for Research on Cancer Handbook Working Group
From the International Agency for Research on Cancer, Lyon, France (B.L.-S., N.V., N.G., K.S.); and the German Cancer Research Center, Heidelberg (F.B.). Address reprint requests to Dr. Lauby-Secretan at the International Agency for Research on Cancer, IARC Handbooks Group (ESC/IHB), 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France, or at secretanb@iarc.fr.

 

参考文献

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Lyon, France: IARC, 2013 (http://globocan.iarc.fr).

2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683-691.

3. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010.

4. Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol 2015;16:1599-1600.

5. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions — volume 100 E: a review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt E):1-538.

6. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med 2016;375:794-798.

7. International Agency for Research on Cancer. Weight control and physical activity. Lyon, France, IARC, 2002.

8. World Cancer Research Fund, American Institute for Cancer Research. Diet, nutrition, physical activity and colorectal cancer: Continuous Update Project 2017 (http://wcrf.org/colorectal-cancer-2017).

9. Cottet V, Jooste V, Fournel I, Bouvier AM, Faivre J, Bonithon-Kopp C. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut 2012;61:1180-1186.

10. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015;64:1637-1649.

11. Carrozzi G, Sampaolo L, Bolognesi L, et al. Economic difficulties keep on influencing early diagnosis of colorectal cancer. Epidemiol Prev 2015;39:210-210. (In Italian.)

12. Honein-AbouHaidar GN, Kastner M, Vuong V, et al. Systematic review and meta-study synthesis of qualitative studies evaluating facilitators and barriers to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2016;25:907-917.

13. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160:171-171.

14. Bray C, Bell LN, Liang H, Collins D, Yale SH. Colorectal cancer screening. WMJ 2017;116:27-33.

15. Coin CG, Wollett FC, Coin JT, Rowland M, DeRamos RK, Dandrea R. Computerized radiology of the colon: a potential screening technique. Comput Radiol 1983;7:215-221.

16. Kronborg O, Jørgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004;39:846-851.

17. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008;95:1029-1036.

18. Pitkäniemi J, Seppä K, Hakama M, et al. Effectiveness of screening for colorectal cancer with a faecal occult-blood test, in Finland. BMJ Open Gastroenterol 2015;2(1):e000034-e000034.

19. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012;61:1036-1040.

20. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-1114.

21. Bertario L, Russo A, Crosignani P, et al. Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case-control study. Eur J Cancer 1999;35:973-977.

22. Bjerrum A, Andersen O, Fischer A, Lindebjerg J, Lynge E. Colorectal cancer mortality 10 years after a single round of guaiac faecal occult blood test (gFOBT) screening: experiences from a Danish screening cohort. BMJ Open Gastroenterol 2016;3(1):e000120-e000120.

23. Faivre J, Tazi MA, El Mrini T, Lejeune C, Benhamiche AM, Dassonville F. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. Br J Cancer 1999;79:680-683.

24. Hamza S, Cottet V, Touillon N, et al. Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer. Dig Liver Dis 2014;46:1121-1125.

25. Lazovich D, Weiss NS, Stevens NG, White E, McKnight B, Wagner EH. A case-control study to evaluate efficacy of screening for faecal occult blood. J Med Screen 1995;2:84-89.

26. Libby G, Brewster DH, McClements PL, et al. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study. Br J Cancer 2012;107:255-259.

27. Malila N, Hakama M, Pukkala E. A 25-year follow-up of a population screened with faecal occult blood test in Finland. Acta Oncol 2007;46:1103-1106.

28. Scheitel SM, Ahlquist DA, Wollan PC, Hagen PT, Silverstein MD. Colorectal cancer screening: a community case-control study of proctosigmoidoscopy, barium enema radiography, and fecal occult blood test efficacy. Mayo Clin Proc 1999;74:1207-1213.

29. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer: a case-control study. Ann Intern Med 1993;118:1-6.

30. Zappa M, Castiglione G, Grazzini G, et al. Effect of faecal occult blood testing on colorectal mortality: results of a population-based case-control study in the district of Florence, Italy. Int J Cancer 1997;73:208-210.

31. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-1607.

32. Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer 2015;121:3221-3229.

33. Giorgi Rossi P, Vicentini M, Sacchettini C, et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol 2015;110:1359-1366.

34. Ventura L, Mantellini P, Grazzini G, et al. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis 2014;46:82-86.

35. Zorzi M, Fedeli U, Schievano E, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut 2015;64:784-790.

36. Costantini AS, Martini A, Puliti D, et al. Colorectal cancer mortality in two areas of Tuscany with different screening exposures. J Natl Cancer Inst 2008;100:1818-1821.

37. Laing SS, Bogart A, Chubak J, Fuller S, Green BB. Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system. Cancer Epidemiol Biomarkers Prev 2014;23:154-159.

38. Parker MA, Robinson MH, Scholefield JH, Hardcastle JD. Psychiatric morbidity and screening for colorectal cancer. J Med Screen 2002;9:7-10.

39. Patel SS, Kilgore ML. Cost effectiveness of colorectal cancer screening strategies. Cancer Control 2015;22:248-258.

40. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointest Endosc 2012;75:612-620.

41. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-1633.

42. Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014;312:606-615.

43. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of “once-only sigmoidoscopy” — SCORE. J Natl Cancer Inst 2002;94:1763-1772.

44. Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet 2017;389:1299-1311.

45. Blom J, Yin L, Lidén A, et al. A 9-year follow-up study of participants and nonparticipants in sigmoidoscopy screening: importance of self-selection. Cancer Epidemiol Biomarkers Prev 2008;17:1163-1168.

46. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.

47. Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009;7:770-775.

48. Manser CN, Bachmann LM, Brunner J, Hunold F, Bauerfeind P, Marbet UA. Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. Gastrointest Endosc 2012;76:110-117.

49. Eldridge RC, Doubeni CA, Fletcher RH, et al. Uncontrolled confounding in studies of screening effectiveness: an example of colonoscopy. J Med Screen 2013;20:198-207.

50. García-Albéniz X, Hsu J, Bretthauer M, Hernán MA. Effectiveness of screening colonoscopy to prevent colorectal cancer among Medicare beneficiaries aged 70 to 79 years: a prospective observational study. Ann Intern Med 2017;166:18-26.

51. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467-g2467.

52. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;315:2576-2594.

53. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA 2016;315:2595-2609.

54. Stoop EM, de Haan MC, de Wijkerslooth TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 2012;13:55-64.

55. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349:2191-2200.

56. Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 2007;357:1403-1412.

57. Johnson CD, Chen M-H, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008;359:1207-1217.

58. Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 2009;58:241-248.

59. Iafrate F, Iussich G, Correale L, et al. Adverse events of computed tomography colonography: an Italian National Survey. Dig Liver Dis 2013;45:645-650.

60. Emilsson L, Holme Ø, Bretthauer M, et al. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther 2017;45:193-204.

61. Elmunzer BJ, Singal AG, Sussman JB, et al. Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointest Endosc 2015;81(3):700-709.e3.

62. Hassan C, Giorgi Rossi P, Camilloni L, et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012;36:929-940.

63. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg 2012;99:1488-1500.

64. Castells A, Quintero E, Álvarez C, et al. Rate of detection of advanced neoplasms in proximal colon by simulated sigmoidoscopy vs fecal immunochemical tests. Clin Gastroenterol Hepatol 2014;12(10):1708-16.e4.

65. Sali L, Mascalchi M, Falchini M, et al. Reduced and full-preparation CT colonography, fecal immunochemical test, and colonoscopy for population screening of colorectal cancer: a randomized trial. J Natl Cancer Inst 2015;108:108-108.

66. Zorzi M, Hassan C, Capodaglio G, et al. Long-term performance of colorectal cancer screening programmes based on the faecal immunochemical test. Gut 2017 November 3 (Epub ahead of print).

服务条款 | 隐私政策 | 联系我们